WallStSmart

Meihua International Medical Technologies Co Ltd (MHUA)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

West Pharmaceutical Services Inc generates 3615% more annual revenue ($3.33B vs $89.55M). WST leads profitability with a 17.0% profit margin vs 10.3%. MHUA trades at a lower P/E of 0.3x. WST earns a higher WallStSmart Score of 61/100 (C+).

MHUA

Avoid

34

out of 100

Grade: F

Growth: 2.0Profit: 6.0Value: 6.7Quality: 8.5
Piotroski: 2/9Altman Z: 5.83

WST

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 2.7Quality: 8.5
Piotroski: 4/9Altman Z: 4.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for MHUA.

WSTSignificantly Overvalued (-47.9%)

Margin of Safety

-47.9%

Fair Value

$166.45

Current Price

$351.02

$184.57 premium

UndervaluedFair: $166.45Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MHUA4 strengths · Avg: 10.0/10
P/E RatioValuation
0.3x10/10

Attractively priced relative to earnings

Price/BookValuation
0.0x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
5.8310/10

Safe zone — low bankruptcy risk

WST3 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.7310/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Operating MarginProfitability
22.5%8/10

Strong operational efficiency at 22.5%

Areas to Watch

MHUA4 concerns · Avg: 2.5/10
Market CapQuality
$425.43M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Revenue GrowthGrowth
-16.2%2/10

Revenue declined 16.2%

EPS GrowthGrowth
-42.0%2/10

Earnings declined 42.0%

WST3 concerns · Avg: 2.7/10
Price/BookValuation
8.3x4/10

Trading at 8.3x book value

PEG RatioValuation
2.912/10

Expensive relative to growth rate

P/E RatioValuation
43.5x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : MHUA

The strongest argument for MHUA centers on P/E Ratio, Price/Book, Debt/Equity.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Debt/Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 22.5%. Revenue growth of 13.8% demonstrates continued momentum.

Bear Case : MHUA

The primary concerns for MHUA are Market Cap, Piotroski F-Score, Revenue Growth.

Bear Case : WST

The primary concerns for WST are Price/Book, PEG Ratio, P/E Ratio. A P/E of 43.5x leaves little room for execution misses.

Key Dynamics to Monitor

MHUA profiles as a declining stock while WST is a mature play — different risk/reward profiles.

WST carries more volatility with a beta of 1.16 — expect wider price swings.

WST is growing revenue faster at 13.8% — sustainability is the question.

WST generates stronger free cash flow (81M), providing more financial flexibility.

Bottom Line

WST scores higher overall (61/100 vs 34/100), backed by strong 17.0% margins and 13.8% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Meihua International Medical Technologies Co Ltd

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Meihua International Medical Technologies Co., Ltd. is engaged in the manufacturing and marketing of medical consumables in the People's Republic of China.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?